Delcath Systems, Inc. (DCTH) Reports Q1 Loss, Misses Revenue EstimatesZacks Investment Research • 05/07/26
Delcath Systems Announces Presentation of New Data on Percutaneous Hepatic Perfusion with Melphalan in Liver-Dominant Metastatic Breast Cancer at ESMO Breast Cancer 2026Business Wire • 05/07/26
Delcath Systems, Inc. Announces Inclusion of CHEMOSAT Hepatic Delivery System for Melphalan as a Recommended Liver-Directed Regional Therapy Option in the ESMO–EURACAN Clinical Practice Guidelines for Uveal MelanomaBusiness Wire • 04/06/26
Delcath Systems to Participate at the Society of Interventional Radiology 2026 MeetingBusiness Wire • 04/01/26
Delcath Systems Announces Publication of CHOPIN Clinical Trial Results in The Lancet OncologyBusiness Wire • 03/03/26
Delcath Systems to Participate at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools ConferenceBusiness Wire • 01/27/26
Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2025 Financial ResultsBusiness Wire • 01/09/26
Delcath Systems Announces Publication of Subgroup Analyses of the Phase 3 FOCUS Study of Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal MelanomaBusiness Wire • 12/31/25
Delcath Systems Announces Publication of 10-Year Single-Center Experience with Percutaneous Hepatic Perfusion in Liver-Dominant Metastatic Uveal MelanomaBusiness Wire • 12/03/25
Delcath Systems Board of Directors Authorizes $25 Million Share Repurchase ProgramBusiness Wire • 11/20/25
Delcath Systems Announces Publication of Expert Narrative Review on Percutaneous Hepatic Perfusion for Liver Metastases from Uveal MelanomaBusiness Wire • 11/18/25
Delcath Systems Announces Publication of Real-World Evidence Supporting Early Use of Liver-Directed Therapy with PHP in Achieving Long-Term Survival for Metastatic Uveal Melanoma PatientsBusiness Wire • 11/13/25
Delcath Systems, Inc. (DCTH) Discusses CHOPIN Trial Results and Preliminary Q3 Financials TranscriptSeeking Alpha • 10/20/25